Figures
Abstract
Increasingly, platelet-rich plasma injections are being used for patients with osteoarthritis and tendinopathy. GPs play an important role in helping patients understand their treatment options and in managing expectations about emerging treatments such as this musculoskeletal ‘biological’ therapy.
Article Extract
In Australia, arthritis and other musculoskeletal conditions account for 13% of the total disease burden; musculoskeletal disease is ranked fourth among disease groups for causes of disability.1 Osteoarthritis affects 2.2 million (9.3% or one in 11 people) nationally and is the eighth most frequently managed problem in general practice.2 As there is currently no cure, treatments are aimed at reducing pain and improving function.
